Evidence
What the research shows
Oral BPC-157 has primarily GI-tract effects; systemic recovery is weaker than subcutaneous BPC-157.
Loading catalog
Pulling latest protocols
Encyclopedia / Recovery
Oral BPC-157 capsules for users avoiding injections.
Evidence
Oral BPC-157 has primarily GI-tract effects; systemic recovery is weaker than subcutaneous BPC-157.
Protocol
8-12 weeks at 250-500 mcg/day oral.
Safety
Generally well tolerated. Avoid in pregnancy / active malignancy.
Best for
Recovery-focused users avoiding injections.
Not for
Acute orthopedic injuries needing local soft-tissue effect.
Build your stack
Pepzilla matches it with the right companions, dosing, and lifestyle rails for your goals — calibrated in 60 seconds.